Dating back to 1951, the partnership between the Dutch Cancer Society and the NKI is a strong one. In 2019, the Dutch Cancer Society and the Netherlands Cancer Institute signed a new cooperation agreement covering the next five years, which includes an annual institutional grant from the Dutch Cancer Society of €16.8 million to support the NKI doing high quality, and impactful cancer research.
Also, the Netherlands Cancer Institute and the Dutch Cancer Society agreed to collaborate on the basis of three thematic subjects:
- Patient impact: How can we speed up the translation of results obtained in the lab to the clinical practice
- Quality of Life: Improving the quality of life of cancer patients and their relatives during and after treatment.
- Access to cancer drugs: Drugs should be made more readily available to patients. To that end, the DCS and the NKI explore new ways to make, register and reimburse cancer drugs.